Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· December 1, 2025

Credo Technology Group Holding Ltd Reports Second Quarter of Fiscal Year 2026 Financial Results

View original at finance.yahoo.com
Credo Technology Group Holding Ltd Reports Second Quarter of Fiscal Year 2026 Financial Results SAN JOSE, Calif., December 01, 2025--(BUSINESS WIRE)--Credo Technology Group Holding Ltd (Credo) (Nasdaq: CRDO), an innovator in providing reliable, energy-efficient, system-level connectivity solutions for the next generati…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • GAAP gross margin is expected to be between 63.8% and 65.8% for Q3 FY2026

    80% confidence
  • In the second quarter Credo delivered revenue of $268.0 million, an increase of 20% sequentially and an extraordinary 272% increase year-over-year

    80% confidence
  • GAAP operating expenses are expected to be between $116.0 million and $120.0 million for Q3 FY2026

    80% confidence
  • The combination of continued growth in core AEC and IC franchises, plus upcoming ramps of ZeroFlap Optics, ALCs, and OmniConnect gearbox solutions gives an outlook with strong revenue growth and profitability through fiscal 2026 and beyond

    80% confidence
  • Revenue is expected to be between $335.0 million and $345.0 million for Q3 FY2026

    80% confidence
  • The results reflect the continued build-out of the world's largest AI training and inference clusters

    80% confidence
  • Non-GAAP operating expenses are expected to be between $68.0 million and $72.0 million for Q3 FY2026

    80% confidence
  • These are the strongest quarterly results in Credo's history

    80% confidence
  • Non-GAAP gross margin is expected to be between 64.0% and 66.0% for Q3 FY2026

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com